61 completed, 11 recruiting, 7 terminated, 2 withdrawn. 69 Phase 1, 17 Phase 2, 7 Phase 3.
Follow Sunshine Lake Pharma Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants Clifutinib, Itraconazole, fluconazole - Healthy Adult Subject | Phase 1 | Not yet recruiting | Sunshine Lake Pharma Co., Ltd. | 80 | 2026-12-31 | 2026-04-27 |
| Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function Larotinib - Esophageal Cancer, Advanced Solid Tumor | Phase 1 | Withdrawn | Sunshine Lake Pharma Co., Ltd. | 2026-10-30 | 2026-09-28 | |
| HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors HEC-921, Oxaliplatin, Capecitabine - Advanced Malignant Solid Tumors | Phase 1 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 110 | 2026-09-18 | 2026-09-24 |
| Single-ascending Dose Study of HEC-151 Injection HEC-151 Injection, Degludec insulin, Placebo - Healthy Adult Male | Phase 1 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 81 | 2026-02-24 | 2026-09-25 |
| A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B HECN30227 injection(SAD), Placebo(MAD), Placebo(SAD) - HBV Infection | Phase 1 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 78 | 2025-12-02 | 2026-08-18 |
| Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF HEC585, Placebo, Pirfenidone - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 472 | 2025-10-27 | 2026-04-21 |
| Clinical Study on the Mass Balance of Clifutinib [14C]Clifutinib - Healthy Adult Male | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 6 | 2025-09-29 | 2026-01-16 |
| A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects HEC-007 injection, Placebo - Healthy Subjects | Phase 1 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 126 | 2025-09-21 | 2026-04-27 |
| A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects HEC169584 capsule, placebo - Non - Alcoholic Steatohepatitis | Phase 1 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 96 | 2025-09-03 | 2026-09-04 |
| ADME Study of [14C] Yiqibuvir in Healthy Male Subjects [14C] Yiqibuvir - Healthy Male Subjects | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 8 | 2023-08-07 | 2024-02-21 |
| A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China Insulin Degludec and Insulin Aspart - Diabetes | Phase 3 | Completed | Sunshine Lake Pharma Co., Ltd. | 414 | 2023-07-06 | 2026-05-01 |
| HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML Clifutinib, LoDAC, Azacitidine - Leukemia, Acute Myeloid (AML) | Phase 3 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 324 | 2023-03-03 | 2026-04-28 |
| A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients HEC585 dose A, HEC585 dose B, Placebo - Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | Phase 2 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 110 | 2023-02-15 | 2026-04-24 |
| Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations CT053PTSA - Advanced NSCLC | Phase 2 | Withdrawn | Sunshine Lake Pharma Co., Ltd. | 2022-11-27 | 2026-05-14 | |
| ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects [14C] Antaitavir Hasophate - Healthy Male Subjects | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 6 | 2022-11-15 | 2023-01-05 |
| Clifutinib Food Effect Study in Healthy Subjects Clifutinib with fed state, Clifutinib with fasted state - Acute Myeloid Leukemia in Children | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 40 | 2022-11-08 | 2023-03-21 |
| Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114 Midazolam Syrup, HEC74647PA, HEC110114 - Healthy Subjects | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 14 | 2022-11-07 | 2022-12-21 |
| A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML Clifutinib Besylate - Acute Myeloid Leukemia, Adult | Phase 1 / Phase 2 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 133 | 2022-10-31 | 2026-05-15 |
| HEC169096 in Participants With Advanced Solid Tumors HEC169096 - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Sunshine Lake Pharma Co., Ltd. | 24 | 2022-10-21 | 2026-10-14 |
| Study on the Body Mass Balance and Biotransformation of [14C]-HEC585 [14C]-HEC585 - Healthy Volunteer | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 6 | 2022-07-26 | 2023-04-13 |
Showing 20 of 83. Sign in to see all of them.
Hepatitis C, Chronic (7) · Idiopathic Pulmonary Fibrosis (7) · Diabetes Mellitus, Type 2 (6) · Hepatitis B, Chronic (5) · Non-alcoholic Fatty Liver Disease (5) · Leukemia, Myeloid, Acute (4) · Depressive Disorder, Major (3) · Esophageal Neoplasms (2) · Sleep Initiation and Maintenance Disorders (2) · Asthma (1) · Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus (1) · Diabetic Nephropathies (1) · Esophageal Squamous Cell Carcinoma (1) · Gout (1)
yimitasvir (5) · Ritonavir (4) · pirfenidone (4) · Sofosbuvir (3) · Food (2) · Itraconazole (2) · Rifampin (2) · entecavir (2) · insulin degludec (2) · nintedanib (2) · Azacitidine (1) · Bevacizumab (1) · Capecitabine (1) · Cytarabine (1) · Decitabine (1)
China (79) · United States (2) · Australia (1)
Yanhua Ding, Doctor (7) · Lai Wei, Doctor (3) · Li Zhang, MD (3) · Ding Yanhua, Doctor (2) · JianMing Xu, Doctor (2) · Jie Jin, Doctor (2) · DongYang Liu, doctor (1) · Guo Jun, PhD (1) · Hong Wang, bachelor (1) · Irene Mirkin, MD (1) · Jia Miao, MD (1) · Jianming Xu, PHD (1) · Jianxiang Wang, Doctor (1) · Jie Hou, doctor (1)
PMID 34688250, PMID 35871497, PMID 38651744, PMID 39673713, PMID 39988055, PMID 41069609